New IPO Opportunity

Capital Raise (Min) $5,000,000
Capital Raise (Max) $8,000,000
Market Cap (Max) $14,850,000
EV on Listing $6,850,000
Issue Price $0.20
Open Date 5/12/2016
Closing Date 10am 7/12/2016
First Day of Trading 22/12/2016*

*Estimated date

INVEST NOW

INVESTMENT OPPORTUNITY

Developing and commercialising medical diagnostic and monitoring
technology to instantly diagnose, monitor and manage chronic diseases & skin diseases using your smartphone.

Lifespot Health operates within the digital health sector and is focused on developing and commercialising medical diagnostic and monitoring technology, which includes the BodyTel System and the Lifespot Skin System.

All IP is 100% controlled by the company and will be part of the listed entity.

Over EUR4.3Million spent to date ($6.2M AUD) with global certifications & first mover advantage.

Revenue generating: Company is already operational in Europe, with existing paying customers including B.Braun, Anycare and TK Pharma.

Potential uplift: Enterprise Value on listing is $6.85
million and trading on an Enterprise Value to Revenue multiple of
only 3.4X on listing.

Scalable technology that is certified: Therapy or treatment decisions based on software products are only allowed for medical devices if it is certified.

Growing sector: The telemedicine sector is expected to reach USD $35 billion by 2020, growing at CAGR of around 14%. There is also an increase in m&a and investments in the area*.

JV opportunities: Most systems on the market are single-sensor and do not cover multi-disease patients.

The Digital Revolution comes to US Healthcare (Goldman Sachs Equity Research, 2015)

INVEST NOW

COMPANY DETAILS

How BodyTel™ Works

• The BodyTel™ solution is a back-end and front-end system that facilitates the management, measurement & monitoring of chronic diseases

• All values measured with BodyTel™ devices, are sent wirelessly in real-time via Bluetooth through a cell phone or home gateway, directly into the patient’s personalized online record

• Patient records are located in BodyTel™’s secure medical-data cloud interface and are available upon request

• This secure database can be individually accessed via the BodyTel™ Center online portal: www.bodytel.com, allowing GPs, surgeons and medical practitioners to attain up-to-date, real-time data on their patients

Competitors Are Providing JV Opportunites

• BodyTel™ is leading the pack in terms of automation and coverage of the value chain

• Many single-disease competitors are on the market, but only a few are covering multi-disease patients, which is a clear point of difference

• Most of the systems on the market are single-sensor, where patients want and are looking for choice

• There are currently no competitors with a comparable multi-role system compatibilty in the market

Customers

B.Braun (55,000+ Employees)
• New contract since April 2016
Software development on average of ~50,000€+ per month (SaaS) and growing MoM
• Usage of the system ~10,000€+ per month
• Large pipeline of development projects filled for the next 6 months

AnyCare (German telemonitoring center)

tk-pharma (diabetes mail-order company)

INVEST NOW

The Lifespot Skin System

SHARE THIS DEAL

COMPANY FINANCIALS

Comparables

Use of Funds

Capital Structure

INVEST NOW

LEADERSHIP

Tilo Brandis

Chairman

Tilo Brandis has held General Management
and CEO roles at Siemens transportation and
automation divisions, for 11 years, and has
held the position of managing director at RailOne, Track-Tec and B2X Care Solutions. Mr
Brandis has extensive experience in
international management and mergers and
acquisitions.

Stefan Schraps

Founder & Chief Scientific Officer

Stefan Schraps is the managing director of
BodyTel GmbH and was one of the founders of
the BodyTel System.

Before his work with BodyTel, Stefan has held
senior positions in fast growing information
technology companies and has been heavily
involved in the ‘telemonitoring’ and
Telemedicine industries since 2006.

Heinrich Emden

Executive Director

Prior to joining BodyTel, Heinrich was largely
focused on telecommunication and information
technology development. at several multinational
organisations including IBM, Continental AG,
Symrise and ATOS.

He coordinates all
internal and external developer teams and is
responsible for
the constant evolution and development of the
BodyTel System.

DOCUMENTS

Prospectus

Term Sheet

Website

Unsubscribe at any time

FAQ

How do I bid?

Register interest by clicking INVEST NOW or by filling out the form above. You will then be taken to the application form where you can place your bid. We will be in touch to confirm your final allocation.

What if I don't have an account with Peak Asset Management?

The shares you bid for will automatically appear in your broking account with the HIN provided. Otherwise, your shares will be on a SRN.

What if I don't have a HIN?

Then your shares will be on a SRN. This will require additional paperwork from your broker.

How do I get in touch?

You may contact us at info@peakassetmanagement.com.au

Disclaimer

Financial Services Guide

The offer described in this notice relates to the issue of new securities by the Issuer. A Prospectus for the offer is available and can be obtained from the Issuer’s website or by way of download from this website. The offer of securities will be made in, or accompanied by, a copy of the Prospectus. Nothing contained in this message and/or any attachment(s) constitutes a personal advice recommendation, solicitation or an offer to buy or sell any securities. Any recommendation or endorsement of this offer is general advice in nature and has not taken into account your personal circumstances or objectives. A person should consider the Prospectus in deciding whether to acquire the securities.

This notice does not constitute an offer or invitation in any place in which, or to any person to whom, it would not be lawful to make such an offer or invitation. The Prospectus does not constitute an offer to sell, or a solicitation of any offer to buy, securities in the United States. The Prospectus has been prepared for publication in Australia and New Zealand.